Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZIAD H YOUNES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1285619874
CMS profile
194746
Location
GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$61,065.07

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZIAD H YOUNES

NPI 1285619874 · CMS profile ID 194746

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $61,065.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $103.9507/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292043 CMS
PFIZER INC. $14.7407/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832667290 CMS
Amgen Inc. $20.5607/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825886181 CMS
Ironwood Pharmaceuticals, Inc $20.5507/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855128235 CMS
AbbVie Inc. $12.7407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292041 CMS
E.R. Squibb & Sons, L.L.C. $81.3507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783437101 CMS
AbbVie Inc. $2.3907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292039 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.3107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820347935 CMS
AbbVie Inc. $19.8207/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292037 CMS
Janssen Scientific Affairs, LLC $900.0007/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788072685 CMS
AbbVie Inc. $101.0006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292035 CMS
Janssen Biotech, Inc. $656.2506/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788072677 CMS
E.R. Squibb & Sons, L.L.C. $99.6106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783437089 CMS
AbbVie Inc. $2.9006/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292033 CMS
Janssen Biotech, Inc. $89.0006/02/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788072679 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $48.6505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850115151 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,015.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820347931 CMS
Intercept Pharmaceuticals, Inc. $10.3005/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836217201 CMS
AbbVie Inc. $1,950.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292031 CMS
Takeda Pharmaceuticals U.S.A., Inc. $870.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820347927 CMS
Eisai Inc. $115.8405/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833754849 CMS
AbbVie Inc. $25.6904/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292029 CMS
Intercept Pharmaceuticals, Inc. $1,000.0003/24/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836217197 CMS
Intercept Pharmaceuticals, Inc. $8.2503/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836217193 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,450.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820347923 CMS
AbbVie Inc. $975.0002/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796292027 CMS
Intercept Pharmaceuticals, Inc. $750.0001/20/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836217191 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,972.22 159
PY2020 $43,458.20 68
PY2021 $61,065.07 77
PY2022 $186,127.26 251
PY2023 $162,436.97 168
PY2024 $277,797.30 247
PY2025 $252,324.21 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $64.26 1
PY2025 Principal investigator $3,862,579.53 370
PY2024 Principal investigator $3,328,915.16 426
PY2023 Principal investigator $3,063,905.12 250
PY2022 Recipient $3,135.55 2
PY2022 Principal investigator $585,955.74 90
PY2021 Recipient $80,681.30 14
PY2021 Principal investigator $466,408.79 179
PY2020 Recipient $17,608.43 6
PY2020 Principal investigator $1,189,628.39 408
PY2019 Recipient $4,385.93 4
PY2019 Principal investigator $2,047,867.28 399

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

371 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $750.00 12/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608422
Principal investigator 1 F. Hoffmann-La Roche AG $31,186.00 12/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608434
Principal investigator 1 F. Hoffmann-La Roche AG $23,113.00 12/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608438
Principal investigator 1 Ipsen Bioscience Inc. $413.73 12/19/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545745
Principal investigator 1 Madrigal Pharmaceuticals $6,662.59 12/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254264
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187889418
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187889984
Principal investigator 1 Gilead Sciences, Inc. $1,563.00 12/16/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206825
Principal investigator 1 F. Hoffmann-La Roche AG $39,108.00 12/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608418
Principal investigator 1 Ipsen Bioscience Inc. $413.73 12/11/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545743
Principal investigator 1 Madrigal Pharmaceuticals $8,977.50 12/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248253686
Principal investigator 1 Madrigal Pharmaceuticals $28,674.00 12/09/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253618
Principal investigator 1 Madrigal Pharmaceuticals $5,670.00 12/09/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253622
Principal investigator 1 Eli Lilly and Company $324.14 12/08/2025 Non-covered Recipient Entity
NORTHWEST CLINICAL RESEARCH CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187887338
Principal investigator 1 ABBVIE INC. $27,119.33 12/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202529414
Principal investigator 1 ABBVIE INC. $8,472.50 12/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202529416
Principal investigator 1 ABBVIE INC. $38,950.89 12/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202529418
Principal investigator 1 ABBVIE INC. $396.36 12/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202529420
Principal investigator 1 F. Hoffmann-La Roche AG $23,118.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608426
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608431
Principal investigator 1 F. Hoffmann-La Roche AG $12,003.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608442
Principal investigator 1 Ipsen Bioscience Inc. $4,875.79 12/04/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545741
Principal investigator 1 Madrigal Pharmaceuticals $650.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253320
Principal investigator 1 Madrigal Pharmaceuticals $36,078.75 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253324
Principal investigator 1 Madrigal Pharmaceuticals $8,775.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253328
Principal investigator 1 Madrigal Pharmaceuticals $100.00 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253331
Principal investigator 1 Madrigal Pharmaceuticals $2,007.11 12/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253335
Principal investigator 1 Genentech, Inc. $34,726.00 11/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608731
Principal investigator 1 Genentech, Inc. $28,325.00 11/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608735
Principal investigator 1 Ipsen Bioscience Inc. $413.73 11/25/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545739
Principal investigator 1 Madrigal Pharmaceuticals $6,021.33 11/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252829
Principal investigator 1 Genentech, Inc. $1,605.00 11/20/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608742
Principal investigator 1 Gilead Sciences, Inc. $2,617.20 11/19/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209580
Principal investigator 1 Gilead Sciences, Inc. $8,192.00 11/18/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206818
Principal investigator 1 Genentech, Inc. $288.00 11/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608707
Principal investigator 1 Genentech, Inc. $12,013.00 11/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608717
Principal investigator 1 Genentech, Inc. $414.00 11/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608722
Principal investigator 1 Genentech, Inc. $813.00 11/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608739
Principal investigator 1 Ipsen Bioscience Inc. $1,404.10 11/14/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545737
Principal investigator 1 Gilead Sciences, Inc. $135.00 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209563
Principal investigator 1 Gilead Sciences, Inc. $1,500.00 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209573
Principal investigator 1 Gilead Sciences, Inc. $540.00 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209590
Principal investigator 1 Gilead Sciences, Inc. $500.00 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209594
Principal investigator 1 Gilead Sciences, Inc. $183.60 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209601
Principal investigator 1 Gilead Sciences, Inc. $1,620.00 11/12/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209609
Principal investigator 1 Genentech, Inc. $8,304.00 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608713
Principal investigator 1 Genentech, Inc. $12,926.00 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608727
Principal investigator 1 Madrigal Pharmaceuticals $300.00 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252384
Principal investigator 1 Madrigal Pharmaceuticals $11,603.25 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252388
Principal investigator 1 Madrigal Pharmaceuticals $6,662.59 11/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252392
Principal investigator 1 ABBVIE INC. $863.08 11/06/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202523545
Principal investigator 1 ABBVIE INC. $266.50 11/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202521473
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $49,013.00 10/29/2025 Non-covered Recipient Entity
GI Center Of The Mid Sout
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235997103
Principal investigator 1 Genentech, Inc. $23,697.00 10/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608693
Principal investigator 1 Gilead Sciences, Inc. $5,614.83 10/29/2025 Non-covered Recipient Entity
GASTRO ONE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204755
Principal investigator 1 Ipsen Bioscience Inc. $5,703.25 10/29/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545735
Principal investigator 1 Madrigal Pharmaceuticals $4,334.85 10/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252153
Principal investigator 1 Eli Lilly and Company $76.65 10/27/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187890186
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271429
Principal investigator 1 Janssen Research & Development, LLC $3,727.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271436
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271463
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271471
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271504
Principal investigator 1 Janssen Research & Development, LLC $343.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271526
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271587
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271604
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271635
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271644
Principal investigator 1 Janssen Research & Development, LLC $343.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271655
Principal investigator 1 Janssen Research & Development, LLC $3,727.00 10/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271728
Principal investigator 1 Genentech, Inc. $32,130.00 10/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608696
Principal investigator 1 Ipsen Bioscience Inc. $827.46 10/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545733
Principal investigator 1 Madrigal Pharmaceuticals $2,929.50 10/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251775
Principal investigator 1 Madrigal Pharmaceuticals $50.00 10/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251779
Principal investigator 1 Genentech, Inc. $17,261.00 10/16/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608681
Principal investigator 1 Ipsen Bioscience Inc. $3,733.41 10/16/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545729
Principal investigator 1 Ipsen Bioscience Inc. $1,571.30 10/16/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545731
Principal investigator 1 Madrigal Pharmaceuticals $8,669.70 10/16/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251500
Principal investigator 1 ABBVIE INC. $7,385.00 10/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202516545
Principal investigator 1 ABBVIE INC. $2,288.25 10/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202516559
Principal investigator 1 Genentech, Inc. $6,188.00 10/09/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608684
Principal investigator 1 Genentech, Inc. $37,345.00 10/09/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608704
Principal investigator 1 Genentech, Inc. $38,408.00 10/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608688
Principal investigator 1 Genentech, Inc. $19,554.00 10/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608700
Principal investigator 1 Ipsen Bioscience Inc. $3,225.25 10/03/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545719
Principal investigator 1 Ipsen Bioscience Inc. $500.00 10/03/2025 Non-covered Recipient Entity
Gastro One
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176545721
Principal investigator 1 Ipsen Bioscience Inc. $1,200.00 10/03/2025 Non-covered Recipient Entity
Gastro One
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176545723
Principal investigator 1 Ipsen Bioscience Inc. $2,000.00 10/03/2025 Non-covered Recipient Entity
Gastro One
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176545725
Principal investigator 1 Ipsen Bioscience Inc. $600.00 10/03/2025 Non-covered Recipient Entity
Gastro One
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). No dispute reported 06/30/2026 1176545727
Principal investigator 1 Madrigal Pharmaceuticals $11,638.70 10/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250956
Principal investigator 1 Madrigal Pharmaceuticals $7,624.10 10/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248250960
Recipient Eli Lilly and Company $64.26 10/02/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187872715
Principal investigator 1 ABBVIE INC. $10,161.45 09/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202512530
Principal investigator 1 F. Hoffmann-La Roche AG $12,439.00 09/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608273
Principal investigator 1 Madrigal Pharmaceuticals $4,334.85 09/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250538
Principal investigator 1 F. Hoffmann-La Roche AG $9,777.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608260
Principal investigator 1 F. Hoffmann-La Roche AG $1,242.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608294
Principal investigator 1 F. Hoffmann-La Roche AG $2,448.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608301
Principal investigator 1 F. Hoffmann-La Roche AG $56,878.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608321
Principal investigator 1 F. Hoffmann-La Roche AG $9,777.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608325
Principal investigator 1 F. Hoffmann-La Roche AG $468.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608337
Principal investigator 1 F. Hoffmann-La Roche AG $29,331.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608345
Principal investigator 1 F. Hoffmann-La Roche AG $88.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608358
Principal investigator 1 F. Hoffmann-La Roche AG $767.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608367
Principal investigator 1 F. Hoffmann-La Roche AG $234.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608371
Principal investigator 1 F. Hoffmann-La Roche AG $2,066.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608378
Principal investigator 1 F. Hoffmann-La Roche AG $351.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608383
Principal investigator 1 F. Hoffmann-La Roche AG $117.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608399
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608405
Principal investigator 1 Ipsen Bioscience Inc. $4,875.79 09/18/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545713
Principal investigator 1 Madrigal Pharmaceuticals $6,662.59 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250169
Principal investigator 1 Gilead Sciences, Inc. $1,223.00 09/16/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206810
Principal investigator 1 F. Hoffmann-La Roche AG $37,040.00 09/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608297
Principal investigator 1 Ipsen Bioscience Inc. $1,556.11 09/12/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545711
Principal investigator 1 ABBVIE INC. $2,255.85 09/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202510192
Principal investigator 1 ABBVIE INC. $17,850.00 09/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202510194
Principal investigator 1 Gilead Sciences, Inc. $4,483.80 09/05/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209556
Principal investigator 1 F. Hoffmann-La Roche AG $8,002.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608254
Principal investigator 1 F. Hoffmann-La Roche AG $468.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608317
Principal investigator 1 F. Hoffmann-La Roche AG $144.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608362
Principal investigator 1 F. Hoffmann-La Roche AG $828.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608375
Principal investigator 1 F. Hoffmann-La Roche AG $19,554.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608387
Principal investigator 1 F. Hoffmann-La Roche AG $144.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608413
Principal investigator 1 Ipsen Bioscience Inc. $4,597.92 09/04/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545709
Principal investigator 1 Madrigal Pharmaceuticals $23,209.88 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249464
Principal investigator 1 Madrigal Pharmaceuticals $500.00 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249469
Principal investigator 1 Madrigal Pharmaceuticals $2,327.74 09/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249471
Principal investigator 1 Ipsen Bioscience Inc. $66.00 09/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545715
Principal investigator 1 Genentech, Inc. $763.00 08/27/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608673
Principal investigator 1 F. Hoffmann-La Roche AG $1,116.00 08/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608246
Principal investigator 1 F. Hoffmann-La Roche AG $36,620.00 08/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608277
Principal investigator 1 F. Hoffmann-La Roche AG $117.00 08/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608306
Principal investigator 1 F. Hoffmann-La Roche AG $1,380.00 08/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608355
Principal investigator 1 Ipsen Bioscience Inc. $994.50 08/26/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545705
Principal investigator 1 Madrigal Pharmaceuticals $2,083.72 08/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248248987
Principal investigator 1 F. Hoffmann-La Roche AG $234.00 08/21/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608290
Principal investigator 1 Madrigal Pharmaceuticals $4,655.48 08/21/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248842
Principal investigator 1 Gilead Sciences, Inc. $54,652.00 08/19/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) No dispute reported 06/30/2026 1229206802
Principal investigator 1 F. Hoffmann-La Roche AG $28,214.00 08/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608333
Principal investigator 1 Ipsen Bioscience Inc. $345.80 08/14/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545717
Principal investigator 1 Madrigal Pharmaceuticals $4,334.85 08/14/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248380
Principal investigator 1 ABBVIE INC. $3,375.00 08/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202504103
Principal investigator 1 ABBVIE INC. $20,322.90 08/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202504107
Principal investigator 1 ABBVIE INC. $2,760.75 08/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202504109
Principal investigator 1 F. Hoffmann-La Roche AG $10,479.00 08/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608251
Principal investigator 1 F. Hoffmann-La Roche AG $29,331.00 08/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608329
Principal investigator 1 Ipsen Bioscience Inc. $413.73 08/07/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545701
Principal investigator 1 Ipsen Bioscience Inc. $981.35 08/07/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545703
Principal investigator 1 Madrigal Pharmaceuticals $4,334.85 08/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248096
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271511
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271627
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/06/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271704
Principal investigator 1 Ipsen Bioscience Inc. $90.00 08/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545707
Principal investigator 1 F. Hoffmann-La Roche AG $4,001.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608264
Principal investigator 1 F. Hoffmann-La Roche AG $48,625.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608281
Principal investigator 1 F. Hoffmann-La Roche AG $414.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608285
Principal investigator 1 F. Hoffmann-La Roche AG $28,980.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608303
Principal investigator 1 F. Hoffmann-La Roche AG $2,511.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608313
Principal investigator 1 F. Hoffmann-La Roche AG $2,898.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608341
Principal investigator 1 F. Hoffmann-La Roche AG $12,009.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608395
Principal investigator 1 F. Hoffmann-La Roche AG $351.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608409
Principal investigator 1 Ipsen Bioscience Inc. $1,511.65 07/31/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545691
Principal investigator 1 Madrigal Pharmaceuticals $2,327.74 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247698
Principal investigator 1 Madrigal Pharmaceuticals $6,581.25 07/30/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247595
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 07/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271671
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271680
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271697
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271713
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 07/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271739
Principal investigator 1 Genentech, Inc. $1,526.00 07/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608677
Principal investigator 1 Intercept Pharmaceuticals, Inc. $980.00 07/25/2025 Non-covered Recipient Entity
GASTRO ONE
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171164
Principal investigator 1 F. Hoffmann-La Roche AG $39,748.00 07/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608269
Principal investigator 1 F. Hoffmann-La Roche AG $8,002.00 07/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608391
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,616.64 07/22/2025 Non-covered Recipient Entity
GASTRO ONE
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171166
Principal investigator 1 Ipsen Bioscience Inc. $5,574.79 07/22/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545687
Principal investigator 1 Ipsen Bioscience Inc. $2,340.00 07/22/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545689
Principal investigator 1 Madrigal Pharmaceuticals $1,809.00 07/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247369
Principal investigator 1 Madrigal Pharmaceuticals $2,007.11 07/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247373
Principal investigator 1 Ipsen Bioscience Inc. $1,511.65 07/17/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545685
Principal investigator 1 Madrigal Pharmaceuticals $4,014.22 07/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247123
Principal investigator 1 Gilead Sciences, Inc. $10,588.50 07/16/2025 Non-covered Recipient Entity
GASTRO ONE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204747
Principal investigator 1 Madrigal Pharmaceuticals $675.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247030
Principal investigator 1 Madrigal Pharmaceuticals $675.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247034
Principal investigator 1 Madrigal Pharmaceuticals $1,404.00 07/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247038
Principal investigator 1 F. Hoffmann-La Roche AG $16,243.00 07/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608351
Principal investigator 1 Ipsen Bioscience Inc. $216.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545677
Principal investigator 1 Ipsen Bioscience Inc. $135.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545679
Principal investigator 1 Ipsen Bioscience Inc. $675.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545681
Principal investigator 1 Ipsen Bioscience Inc. $1,823.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545693
Principal investigator 1 Ipsen Bioscience Inc. $405.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545695
Principal investigator 1 Ipsen Bioscience Inc. $223.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545697
Principal investigator 1 Ipsen Bioscience Inc. $223.00 07/10/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545699
Principal investigator 1 Madrigal Pharmaceuticals $6,662.59 07/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246778
Principal investigator 1 Madrigal Pharmaceuticals $16,420.62 07/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248246782
Principal investigator 1 Madrigal Pharmaceuticals $300.00 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246420
Principal investigator 1 Madrigal Pharmaceuticals $22,244.63 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246424
Principal investigator 1 Madrigal Pharmaceuticals $1,768.50 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246428
Principal investigator 1 Madrigal Pharmaceuticals $4,014.22 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246433
Principal investigator 1 Madrigal Pharmaceuticals $18,049.51 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246437
Principal investigator 1 Madrigal Pharmaceuticals $13,685.26 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246441
Principal investigator 1 Madrigal Pharmaceuticals $400.00 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246445
Principal investigator 1 Madrigal Pharmaceuticals $1,768.50 07/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246449
Principal investigator 1 ABBVIE INC. $2,463.75 07/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202496823
Principal investigator 1 ABBVIE INC. $530.40 07/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202496825
Principal investigator 1 Madrigal Pharmaceuticals $35,775.00 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248246290
Principal investigator 1 Ipsen Bioscience Inc. $90.00 07/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545683
Principal investigator 1 Genentech, Inc. $234.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608491
Principal investigator 1 Genentech, Inc. $1,242.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608495
Principal investigator 1 Genentech, Inc. $3,999.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608533
Principal investigator 1 Genentech, Inc. $38,874.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608553
Principal investigator 1 Genentech, Inc. $138.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608562
Principal investigator 1 Genentech, Inc. $117.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608583
Principal investigator 1 Genentech, Inc. $279.00 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608642
Principal investigator 1 Ipsen Bioscience Inc. $3,728.47 06/24/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545673
Principal investigator 1 Madrigal Pharmaceuticals $4,514.40 06/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246211
Principal investigator 1 Genentech, Inc. $1,104.00 06/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608529
Principal investigator 1 Genentech, Inc. $9,777.00 06/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608545
Principal investigator 1 Genentech, Inc. $27,965.00 06/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608594
Principal investigator 1 Genentech, Inc. $20,343.00 06/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608631
Principal investigator 1 Ipsen Bioscience Inc. $1,097.92 06/19/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545671
Principal investigator 1 Madrigal Pharmaceuticals $4,014.22 06/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245945
Principal investigator 1 Ipsen Bioscience Inc. $7,500.17 06/12/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545661
Principal investigator 1 Ipsen Bioscience Inc. $1,404.10 06/12/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545663
Principal investigator 1 Ipsen Bioscience Inc. $669.50 06/12/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545665
Principal investigator 1 Ipsen Bioscience Inc. $1,072.50 06/12/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545667
Principal investigator 1 Ipsen Bioscience Inc. $104.00 06/12/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545669
Principal investigator 1 Madrigal Pharmaceuticals $4,334.85 06/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245569
Principal investigator 1 Eli Lilly and Company $1,095.09 06/11/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187889064
Principal investigator 1 Genentech, Inc. $763.00 06/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608669
Principal investigator 1 Eli Lilly and Company $1,014.78 06/10/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890184
Principal investigator 1 Genentech, Inc. $10,000.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608513
Principal investigator 1 Genentech, Inc. $117.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608558
Principal investigator 1 Genentech, Inc. $837.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608569
Principal investigator 1 Genentech, Inc. $1,104.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608578
Principal investigator 1 Genentech, Inc. $28,980.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608587
Principal investigator 1 Genentech, Inc. $690.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608590
Principal investigator 1 Genentech, Inc. $351.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608597
Principal investigator 1 Genentech, Inc. $9,777.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608610
Principal investigator 1 Genentech, Inc. $19,320.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608623
Principal investigator 1 Genentech, Inc. $351.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608629
Principal investigator 1 Genentech, Inc. $2,200.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608636
Principal investigator 1 Madrigal Pharmaceuticals $11,080.13 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245093
Principal investigator 1 Madrigal Pharmaceuticals $200.00 06/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245098
Principal investigator 1 ABBVIE INC. $5,303.20 06/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202490075
Principal investigator 1 ABBVIE INC. $2,255.85 06/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202490077
Principal investigator 1 Ipsen Bioscience Inc. $90.00 06/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545675
Principal investigator 1 ABBVIE INC. $4,742.40 05/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202486835
Principal investigator 1 ABBVIE INC. $66,495.00 05/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202486837
Principal investigator 1 ABBVIE INC. $11,302.20 05/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202486843
Principal investigator 1 ABBVIE INC. $1,430.00 05/29/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202486845
Principal investigator 1 Ipsen Bioscience Inc. $981.35 05/28/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545657
Principal investigator 1 Madrigal Pharmaceuticals $4,014.22 05/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244740
Principal investigator 1 Genentech, Inc. $14,883.00 05/27/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608574
Principal investigator 1 Genentech, Inc. $14,155.00 05/27/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608614
Principal investigator 1 Genentech, Inc. $763.00 05/23/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608654
Principal investigator 1 Ipsen Bioscience Inc. $1,564.65 05/22/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545655
Principal investigator 1 Madrigal Pharmaceuticals $4,014.22 05/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244381
Principal investigator 1 Genentech, Inc. $10,951.00 05/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608606
Principal investigator 1 Madrigal Pharmaceuticals $22,353.98 05/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243957
Principal investigator 1 ABBVIE INC. $9,055.80 05/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202484277
Principal investigator 1 Genentech, Inc. $7,108.00 05/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608506
Principal investigator 1 Genentech, Inc. $3,204.00 05/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608538
Principal investigator 1 Ipsen Bioscience Inc. $5,988.52 05/08/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545653
Principal investigator 1 ABBVIE INC. $3,853.90 05/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202482655
Principal investigator 1 ABBVIE INC. $2,193.68 05/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202482657
Principal investigator 1 Genentech, Inc. $202,195.00 05/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608651
Principal investigator 1 Gilead Sciences, Inc. $1,030.77 05/07/2025 Non-covered Recipient Entity
GASTRO ONE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204741
Principal investigator 1 Ipsen Bioscience Inc. $90.00 05/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545659
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,944.10 04/30/2025 Non-covered Recipient Entity
TENNESSEE COMPREHENSIVE LUNG AND SLEEP CENTER
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185546101
Principal investigator 1 Genentech, Inc. $3,999.00 04/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608518
Principal investigator 1 Ipsen Bioscience Inc. $6,672.71 04/28/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545649
Principal investigator 1 Ipsen Bioscience Inc. $4,726.25 04/28/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545651
Principal investigator 1 Janssen Research & Development, LLC $4,175.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271405
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271412
Principal investigator 1 Janssen Research & Development, LLC $3,875.35 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271419
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271443
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271458
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271478
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271487
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271495
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271534
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271544
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271552
Principal investigator 1 Janssen Research & Development, LLC $3,875.35 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271560
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271565
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271575
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271582
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271596
Principal investigator 1 Janssen Research & Development, LLC $348.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271612
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271620
Principal investigator 1 Janssen Research & Development, LLC $348.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271648
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271663
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271689
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271721
Principal investigator 1 Janssen Research & Development, LLC $3,609.40 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271746
Principal investigator 1 Janssen Research & Development, LLC $8,800.00 04/28/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271753
Principal investigator 1 Genentech, Inc. $319,206.00 04/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608660
Principal investigator 1 Ipsen Bioscience Inc. $5,980.00 04/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545637
Principal investigator 1 Ipsen Bioscience Inc. $955.00 04/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545639
Principal investigator 1 Ipsen Bioscience Inc. $72.80 04/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545643
Principal investigator 1 Ipsen Bioscience Inc. $8,580.00 04/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545645
Principal investigator 1 Ipsen Bioscience Inc. $780.00 04/23/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545647
Principal investigator 1 ABBVIE INC. $5,879.25 04/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478067
Principal investigator 1 ABBVIE INC. $627.75 04/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478072
Principal investigator 1 ABBVIE INC. $41,850.00 04/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478075
Principal investigator 1 ABBVIE INC. $7,807.05 04/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478079
Principal investigator 1 Genentech, Inc. $10,658.00 04/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608523
Principal investigator 1 Genentech, Inc. $2,514.00 04/15/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608527
Principal investigator 1 Ipsen Bioscience Inc. $5,224.70 04/15/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545635
Principal investigator 1 Genentech, Inc. $152,600.00 04/09/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608665
Principal investigator 1 Genentech, Inc. $3,969.00 04/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608627
Principal investigator 1 Ipsen Bioscience Inc. $1,880.91 04/08/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545633
Principal investigator 1 Madrigal Pharmaceuticals $18,442.36 04/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241902
Principal investigator 1 ABBVIE INC. $3,343.84 04/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202474395
Principal investigator 1 ABBVIE INC. $10,312.65 04/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202474399
Principal investigator 1 Genentech, Inc. $7,454.00 04/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211608542
Principal investigator 1 Genentech, Inc. $9,777.00 04/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608601
Principal investigator 1 Genentech, Inc. $9,777.00 04/01/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608565
Principal investigator 1 Ipsen Bioscience Inc. $5,161.06 04/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545631
Principal investigator 1 Ipsen Bioscience Inc. $90.00 04/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545641
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,620.00 03/27/2025 Non-covered Recipient Entity
GASTRO ONE
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171162
Principal investigator 1 Genentech, Inc. $2,222.00 03/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608460
Principal investigator 1 Ipsen Bioscience Inc. $1,925.38 03/25/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545627
Principal investigator 1 Genentech, Inc. $7,804.00 03/19/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608479
Principal investigator 1 Gilead Sciences, Inc. $19,915.20 03/19/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229209548
Principal investigator 1 Ipsen Bioscience Inc. $1,511.65 03/19/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545623
Principal investigator 1 Ipsen Bioscience Inc. $1,571.30 03/19/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545625
Principal investigator 1 Ipsen Bioscience Inc. $446.00 03/14/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545619
Principal investigator 1 Ipsen Bioscience Inc. $2,349.00 03/14/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545621
Principal investigator 1 Ipsen Bioscience Inc. $8,354.72 03/11/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545615
Principal investigator 1 Ipsen Bioscience Inc. $6,000.00 03/11/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545617
Principal investigator 1 ABBVIE INC. $3,299.40 03/10/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202462216
Principal investigator 1 Genentech, Inc. $763.00 03/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608450
Principal investigator 1 Madrigal Pharmaceuticals $28,870.38 03/06/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240354
Principal investigator 1 Madrigal Pharmaceuticals $48,039.26 03/06/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240360
Principal investigator 1 Genentech, Inc. $66,533.00 03/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608455
Principal investigator 1 Genentech, Inc. $39,108.00 03/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608464
Principal investigator 1 Genentech, Inc. $3,174.00 03/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608469
Principal investigator 1 Genentech, Inc. $1,100.00 03/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608472
Principal investigator 1 Ipsen Bioscience Inc. $32,977.00 03/04/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545613
Principal investigator 1 Ipsen Bioscience Inc. $90.00 03/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545629
Principal investigator 1 Genentech, Inc. $2,200.00 02/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608499
Principal investigator 1 Genentech, Inc. $14,726.00 02/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608619
Principal investigator 1 Genentech, Inc. $10,000.00 02/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608639
Principal investigator 1 Genentech, Inc. $9,660.00 02/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211608646
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,616.64 02/20/2025 Non-covered Recipient Entity
GASTRO ONE
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis No dispute reported 06/30/2026 1248171160
Principal investigator 1 Madrigal Pharmaceuticals $7,074.00 02/13/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239718
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,286.00 02/12/2025 Non-covered Recipient Entity
Gastro One
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235997225
Principal investigator 1 ABBVIE INC. $4,719.60 02/07/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202450227
Principal investigator 1 Janssen Research & Development, LLC $8.50 02/07/2025 Non-covered Recipient Entity
Gastro One
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271519
Principal investigator 1 ABBVIE INC. $1,502.04 02/06/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202447874
Principal investigator 1 Madrigal Pharmaceuticals $44,983.70 02/06/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239163
Principal investigator 1 Madrigal Pharmaceuticals $6,075.00 02/06/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239168
Principal investigator 1 Madrigal Pharmaceuticals $52,289.90 02/06/2025 Non-covered Recipient Entity
GASTRO ONE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239172
Principal investigator 1 Ipsen Bioscience Inc. $981.35 02/05/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545609
Principal investigator 1 Ipsen Bioscience Inc. $90.00 02/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545611
Principal investigator 1 AstraZeneca Pharmaceuticals LP $103,170.25 01/31/2025 Non-covered Recipient Entity
GASTRO ONE
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185546099
Principal investigator 1 Gilead Sciences, Inc. $8,707.14 01/29/2025 Non-covered Recipient Entity
GASTRO ONE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229204733
Principal investigator 1 Eli Lilly and Company $110,867.00 01/28/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187889402
Principal investigator 1 Eli Lilly and Company $877.05 01/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187871309
Principal investigator 1 Janssen Research & Development, LLC $2,457.85 01/27/2025 Non-covered Recipient Entity
Gastroenterology Ctr Of The Midsouth
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175271451
Principal investigator 1 Eli Lilly and Company $7.65 01/15/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1187889404
Principal investigator 1 Genentech, Inc. $61,803.00 01/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608445
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,734.60 01/13/2025 Non-covered Recipient Entity
GASTRO ONE
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1223273893
Principal investigator 1 Eli Lilly and Company $74,946.60 01/10/2025 Non-covered Recipient Entity
SFCT A MEMBER OF THE ALLIANCE INC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1187891696
Principal investigator 1 Ipsen Bioscience Inc. $981.35 01/07/2025 Non-covered Recipient Entity
Gastro One
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176545607
Principal investigator 1 ABBVIE INC. $122.88 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202436401
Principal investigator 1 ABBVIE INC. $1,928.10 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202436405
Principal investigator 1 ABBVIE INC. $4,511.70 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202436408
Principal investigator 1 ABBVIE INC. $1,130.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY CENTER OF THE MIDSOUTH
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202436464
Principal investigator 1 Ipsen Bioscience Inc. $90.00 01/01/2025 Non-covered Recipient Entity
Gastro One
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545605